Biogen stock steadies as earnings and guidance stay in view
Published on 08/24/2026 at 12:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Biogen Inc. (US09062X1037) opened at $216.78 on August 24, 2026, with a market value of $32.03 billion and a 52-week range of $131.52 to $222.15. The share sits close to its high after second-quarter earnings of $3.60 a share on $2.74 billion of revenue, both reported by market data on August 23, 2026.
Second-quarter mix
The latest reported quarter showed revenue up 3.4% year over year to $2.74 billion, while EPS fell from $5.47 in the same quarter of 2025 to $3.60. That gap matters because Biogen also kept FY 2026 guidance at $12.00 to $13.00 per share, a range that gives the stock a clear earnings reference point.
Consensus remains a second layer of support. Market data compiled on August 24, 2026 shows an average target price of $227.07 and a Moderate Buy rating, which leaves the stock trading below that average even after the move toward the top of its yearly range.
Trading setup
Biogen's 200-day simple moving average stands at $194.58 and the 50-day average at $205.53, so the current level remains above both trend markers. The combination of a $216.78 open, a $222.15 52-week high and a $32.03 billion market cap keeps the chart and valuation in the same conversation.
A stronger-than-expected quarter and a held guidance range have done more for the share than any single headline, because investors can now compare the latest $3.60 EPS with the $12.00 to $13.00 full-year target. The next test is whether subsequent quarters keep revenue growth positive after the 3.4% year-over-year gain in the second quarter.
Skyrizi and Beyond
Biogen's product mix still matters, and the company continues to lean on neuroscience and rare-disease treatments that support the reported quarter. That portfolio framing is important because the latest numbers show a business that is still producing billions in quarterly revenue while refining its earnings path.
Biogen shares
Biogen shares opened at $216.78 on August 24, 2026, against a 52-week high of $222.15 and a 52-week low of $131.52.
Fact box
Company: Biogen Inc.
ISIN: US09062X1037
Ticker: BIIB
Exchange: Nasdaq
Price (as of August 24, 2026, 9:30 a.m. ET): $216.78 USD
Market cap: $32.03 billion (as of August 24, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq-100
Next earnings date: November 4, 2026
More on Biogen stock
Biogen Inc. remains a large-cap biotechnology name whose quarterly revenue, earnings power and guidance continue to anchor the stock's near-term trading range.
